- Home
- ONCO vs RDHL Comparison
ONCO vs RDHL Comparison
Compare ONCO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.3M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ONCO | RDHL |
|---|---|---|
| Price | $0.74 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 209.2K |
| Earning Date | 11-12-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $815,371.00 | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.48 |
| 52 Week High | $6.73 | $2.26 |
Technical Indicators
Market Signals| Indicator | ONCO | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 34.08 |
| Support Level | $0.54 | N/A |
| Resistance Level | $0.98 | $1.07 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 20.87 | 12.97 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.